Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...
Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...
Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...
Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...
Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...
Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...
Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.